Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.

doi:10.1002/(sici)1097-0347(199808)20:5<385::aid-hed5>3.0.co;2-u

Article

Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.

Head & neck - 1 Aug 1998

Langer C J, Schaebler D, Sauter E, DeMaria D, Johnson C, Reilly D M, Clark J, Leighton J, Aks C, Litwin S, Ridge J A

Abstract excerpt

BACKGROUND: 5-Fluorouracil (5-FU), as a single agent, produces a 15% response rate in advanced squamous cell carcinoma of the head and neck (SCCHN). N-phosphonacetyl-L-aspartate (PALA) inhibits pyrimidine biosynthesis and increases incorporation of 5-FU metabolites into ribonucleic acid (RNA). Recombinant alpha interferon-2b (rIFN-alpha-2b) may inhibit 5-FU clearance and blunt reflex rise in thymidylate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.

Abstract excerpt

Topics

Related research